A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B
Latest Information Update: 08 Sep 2026
At a glance
- Drugs CRMA 1001 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors nChroma Bio
Most Recent Events
- 27 Jul 2026 This trial has been Temporarily halted in France, according to a Clinical Trials Information System record.
- 29 Jan 2026 Status changed from not yet recruiting to recruiting.
- 28 Jan 2026 According to a nChroma Bio media release, the first patient has been dosed in the trial.